Ovarian cancer trials in Denmark

In Denmark 22 Also abroad 795

22 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Where
Aalborg, Copenhagen Oe, Herlev, Vejle
Age
18 years and over
People
770 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00
Phase 3Taking people
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Where
Aalborg, Aarhus N, Herlev, Odense C
Age
18 years and over
People
900 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07318558 · EU 2023-508047-40-00
Phase 3Taking people
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Where
Aalborg, Copenhagen, Roskilde
Age
18 years and over
People
420 worldwide
Run by
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Aarhus N, Copenhagen, Odense
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 3Taking people
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Where
Copenhagen, Vejle
Age
18 years and over
People
1,630 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00
Phase 3Taking people
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Where
Aalborg
Age
18 years and over
People
270 worldwide
Run by
Verastem, Inc.
See details and how to joinNCT06072781 · EU 2023-508204-38-00
Phase 3Taking people
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Where
Aarhus N, Copenhagen Oe, Roskilde
Age
18 years and over
People
582 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06819007 · EU 2024-516982-35-00
Phase 2Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Where
Aalborg, Herlev, Odense C
Age
18 years and over
People
400 worldwide
Run by
AbbVie
See details and how to joinNCT07059845 · EU 2025-521606-18-00
Phase 1Taking people
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
Where
Copenhagen Oe
Age
18 years and over
People
285 worldwide
Run by
AbbVie
See details and how to joinNCT07278336 · EU 2025-522209-40-00
Phase 1Taking people
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Where
Herlev
Age
15 years and over
People
282 worldwide
Run by
Xencor, Inc.
See details and how to joinNCT06276491
Phase 1Taking people
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Where
Copenhagen Oe, Odense C
Age
18 years and over
People
234 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06997029 · EU 2025-524334-26-01
Phase 3Taking people
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
Where
Aalborg, Copenhagen Oe, Roskilde
Age
18 years and over
People
544 worldwide
Run by
Genmab
See details and how to joinNCT07225270 · EU 2025-522167-15-00
Phase 1/2Taking people
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Where
Copenhagen, Herlev
Age
18 years and over
People
250 worldwide
Run by
BioInvent International AB
See details and how to joinNCT04752826 · EU 2023-509847-29-00
Phase 1Taking people
Normethermic Intraperitoneal Chemotherapy - a Novel Concept for Local Treatment of the Elderly and Fragile Women With Advanced Ovarian Cancer?
Where
Odense C
Age
70 years and over
People
10
Run by
Odense University Hospital
See details and how to joinNCT07733505 · EU 2025-522269-30-00
Phase 3Taking people
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Where
Aalborg, Aarhus N, Odense C, Vejle
Age
18 years and over
People
1,100 worldwide
Run by
AstraZeneca
See details and how to joinNCT07218809 · EU 2025-520466-22-00
Phase 2Taking people
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Where
Odense C
Age
18 years and over
People
37 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT04641247 · EU 2023-506618-29-00
No phaseTaking people
Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
Where
København Ø
Age
18 years to 100 years
People
1,000
Run by
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
See details and how to joinNCT05574673
Phase 1Taking people
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Where
Copenhagen Oe
Age
18 years and over
People
263 worldwide
Run by
OnCusp Therapeutics, Inc.
See details and how to joinNCT06234423 · EU 2024-519862-33-01
Phase 2Taking people
IMPROCAS - Improved Prediction of Ovarian Cancer Surgery
Where
Aarhus N
Age
18 years and over
People
40
Run by
Aarhus University
See details and how to join2023-503398-39-00 · EU 2023-503398-39-00
No phaseTaking people
Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker
Where
Aarhus
Age
18 years and over
People
300
Run by
University of Aarhus
See details and how to joinNCT05763511
No phaseTaking people
Improved Diagnosis of Ovarian Cancer
Where
Aarhus
People
1,700
Run by
University of Aarhus
See details and how to joinNCT05842629
No phaseTaking people
FRAGINOC Study: Screening and Geriatric Assessment and Intervention in Older Patients With Epithelial Ovarian Cancer
Where
Copenhagen, Herlev, Odense, Roskilde, Vejle
Age
70 years to 120 years
People
300
Run by
Odense University Hospital
See details and how to joinNCT05810701